Sleep and circadian dysregulation in depressive illness. Pharmacological implications.
- Autores
- Cardinali, Daniel Pedro; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.
- Año de publicación
- 2011
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness, advances or delays in the circadian phase, or changes in rhythms´ amplitude, being documented in patients with major depressive disorder (MDD), seasonal affective disorder or bipolar disorder. The disturbances in the amplitude and rhythm of melatonin secretion that occur in patients with depression resemble those seen in subjects with chronobiological disorders, thus suggesting that a link between chronobiological disturbances and depressed mood exists. Studies testing variants of genes that control the circadian system have reported circadian gene polymorphisms in depressive illness. Although many antidepressants such as the tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, several serotonin receptor antagonists and selective serotonin reuptake inhibitors (SSRIs) have all been found successful in treating depression, their use is often associated with a disruptive effect on the sleep/wake cycle. SSRIs, currently the most widely prescribed of the antidepressants, are well known for their exacerbation of insomnia. The recently introduced melatonin agonist and selective serotonin antagonist antidepressant, agomelatine, which has melatonin MT1 and MT2 receptor agonist and 5-HT2c antagonist properties, has been useful in treating patients with MDD. Its rapid onset of action and effectiveness in improving the mood of depressed patients has been attributed to its ability to improve sleep/wake cycle quality. Thus, current conceptualization of depressive illness needs to be expanded to include the role of circadian dysregulation in the development of the disease.
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pandi Perumal, Seithikurippu R.. No especifíca;
Fil: Brown, Gregory M.. No especifíca; - Materia
-
DEPRESION
SUEÑO
RITIMOS CIRCADIANOS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/194457
Ver los metadatos del registro completo
id |
CONICETDig_8bf6b6d1af338728960bbd111816b253 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/194457 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Sleep and circadian dysregulation in depressive illness. Pharmacological implications.Cardinali, Daniel PedroPandi Perumal, Seithikurippu R.Brown, Gregory M.DEPRESIONSUEÑORITIMOS CIRCADIANOShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness, advances or delays in the circadian phase, or changes in rhythms´ amplitude, being documented in patients with major depressive disorder (MDD), seasonal affective disorder or bipolar disorder. The disturbances in the amplitude and rhythm of melatonin secretion that occur in patients with depression resemble those seen in subjects with chronobiological disorders, thus suggesting that a link between chronobiological disturbances and depressed mood exists. Studies testing variants of genes that control the circadian system have reported circadian gene polymorphisms in depressive illness. Although many antidepressants such as the tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, several serotonin receptor antagonists and selective serotonin reuptake inhibitors (SSRIs) have all been found successful in treating depression, their use is often associated with a disruptive effect on the sleep/wake cycle. SSRIs, currently the most widely prescribed of the antidepressants, are well known for their exacerbation of insomnia. The recently introduced melatonin agonist and selective serotonin antagonist antidepressant, agomelatine, which has melatonin MT1 and MT2 receptor agonist and 5-HT2c antagonist properties, has been useful in treating patients with MDD. Its rapid onset of action and effectiveness in improving the mood of depressed patients has been attributed to its ability to improve sleep/wake cycle quality. Thus, current conceptualization of depressive illness needs to be expanded to include the role of circadian dysregulation in the development of the disease.Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pandi Perumal, Seithikurippu R.. No especifíca;Fil: Brown, Gregory M.. No especifíca;Giovanni Fioriti2011-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/194457Cardinali, Daniel Pedro; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.; Sleep and circadian dysregulation in depressive illness. Pharmacological implications.; Giovanni Fioriti; Clinical Neuropsychiatry; 8; 6; 12-2011; 321-3381724-4935CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.clinicalneuropsychiatry.org/download/sleep-and-circadian-dysregulation-in-depressive-illness-pharmacological-implications/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:43:41Zoai:ri.conicet.gov.ar:11336/194457instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:43:41.228CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Sleep and circadian dysregulation in depressive illness. Pharmacological implications. |
title |
Sleep and circadian dysregulation in depressive illness. Pharmacological implications. |
spellingShingle |
Sleep and circadian dysregulation in depressive illness. Pharmacological implications. Cardinali, Daniel Pedro DEPRESION SUEÑO RITIMOS CIRCADIANOS |
title_short |
Sleep and circadian dysregulation in depressive illness. Pharmacological implications. |
title_full |
Sleep and circadian dysregulation in depressive illness. Pharmacological implications. |
title_fullStr |
Sleep and circadian dysregulation in depressive illness. Pharmacological implications. |
title_full_unstemmed |
Sleep and circadian dysregulation in depressive illness. Pharmacological implications. |
title_sort |
Sleep and circadian dysregulation in depressive illness. Pharmacological implications. |
dc.creator.none.fl_str_mv |
Cardinali, Daniel Pedro Pandi Perumal, Seithikurippu R. Brown, Gregory M. |
author |
Cardinali, Daniel Pedro |
author_facet |
Cardinali, Daniel Pedro Pandi Perumal, Seithikurippu R. Brown, Gregory M. |
author_role |
author |
author2 |
Pandi Perumal, Seithikurippu R. Brown, Gregory M. |
author2_role |
author author |
dc.subject.none.fl_str_mv |
DEPRESION SUEÑO RITIMOS CIRCADIANOS |
topic |
DEPRESION SUEÑO RITIMOS CIRCADIANOS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness, advances or delays in the circadian phase, or changes in rhythms´ amplitude, being documented in patients with major depressive disorder (MDD), seasonal affective disorder or bipolar disorder. The disturbances in the amplitude and rhythm of melatonin secretion that occur in patients with depression resemble those seen in subjects with chronobiological disorders, thus suggesting that a link between chronobiological disturbances and depressed mood exists. Studies testing variants of genes that control the circadian system have reported circadian gene polymorphisms in depressive illness. Although many antidepressants such as the tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, several serotonin receptor antagonists and selective serotonin reuptake inhibitors (SSRIs) have all been found successful in treating depression, their use is often associated with a disruptive effect on the sleep/wake cycle. SSRIs, currently the most widely prescribed of the antidepressants, are well known for their exacerbation of insomnia. The recently introduced melatonin agonist and selective serotonin antagonist antidepressant, agomelatine, which has melatonin MT1 and MT2 receptor agonist and 5-HT2c antagonist properties, has been useful in treating patients with MDD. Its rapid onset of action and effectiveness in improving the mood of depressed patients has been attributed to its ability to improve sleep/wake cycle quality. Thus, current conceptualization of depressive illness needs to be expanded to include the role of circadian dysregulation in the development of the disease. Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Pandi Perumal, Seithikurippu R.. No especifíca; Fil: Brown, Gregory M.. No especifíca; |
description |
Circadian rhythm abnormalities, as shown by sleep/wake cycle disturbances, constitute one the most prevalent signs of depressive illness, advances or delays in the circadian phase, or changes in rhythms´ amplitude, being documented in patients with major depressive disorder (MDD), seasonal affective disorder or bipolar disorder. The disturbances in the amplitude and rhythm of melatonin secretion that occur in patients with depression resemble those seen in subjects with chronobiological disorders, thus suggesting that a link between chronobiological disturbances and depressed mood exists. Studies testing variants of genes that control the circadian system have reported circadian gene polymorphisms in depressive illness. Although many antidepressants such as the tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, several serotonin receptor antagonists and selective serotonin reuptake inhibitors (SSRIs) have all been found successful in treating depression, their use is often associated with a disruptive effect on the sleep/wake cycle. SSRIs, currently the most widely prescribed of the antidepressants, are well known for their exacerbation of insomnia. The recently introduced melatonin agonist and selective serotonin antagonist antidepressant, agomelatine, which has melatonin MT1 and MT2 receptor agonist and 5-HT2c antagonist properties, has been useful in treating patients with MDD. Its rapid onset of action and effectiveness in improving the mood of depressed patients has been attributed to its ability to improve sleep/wake cycle quality. Thus, current conceptualization of depressive illness needs to be expanded to include the role of circadian dysregulation in the development of the disease. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-12 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/194457 Cardinali, Daniel Pedro; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.; Sleep and circadian dysregulation in depressive illness. Pharmacological implications.; Giovanni Fioriti; Clinical Neuropsychiatry; 8; 6; 12-2011; 321-338 1724-4935 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/194457 |
identifier_str_mv |
Cardinali, Daniel Pedro; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.; Sleep and circadian dysregulation in depressive illness. Pharmacological implications.; Giovanni Fioriti; Clinical Neuropsychiatry; 8; 6; 12-2011; 321-338 1724-4935 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.clinicalneuropsychiatry.org/download/sleep-and-circadian-dysregulation-in-depressive-illness-pharmacological-implications/ |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Giovanni Fioriti |
publisher.none.fl_str_mv |
Giovanni Fioriti |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614472387264512 |
score |
13.070432 |